Literature DB >> 25803575

Mad2 and BubR1: chemotherapeutic coordinators in gastric cancer.

Makoto Iimori1, Hiroyuki Kitao, Yoshihiko Maehara.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25803575      PMCID： PMC4612571          DOI： 10.1080/15384101.2015.1018051

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  7 in total

1.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

Authors:  Yung-Jue Bang; Eric Van Cutsem; Andrea Feyereislova; Hyun C Chung; Lin Shen; Akira Sawaki; Florian Lordick; Atsushi Ohtsu; Yasushi Omuro; Taroh Satoh; Giuseppe Aprile; Evgeny Kulikov; Julie Hill; Michaela Lehle; Josef Rüschoff; Yoon-Koo Kang
Journal:  Lancet       Date:  2010-08-19       Impact factor: 79.321

Review 2.  Paclitaxel chemotherapy for the treatment of gastric cancer.

Authors:  Junichi Sakamoto; Takanori Matsui; Yasuhiro Kodera
Journal:  Gastric Cancer       Date:  2009-06-27       Impact factor: 7.370

Review 3.  Global cancer statistics in the year 2000.

Authors:  D M Parkin
Journal:  Lancet Oncol       Date:  2001-09       Impact factor: 41.316

Review 4.  Senescence in tumours: evidence from mice and humans.

Authors:  Manuel Collado; Manuel Serrano
Journal:  Nat Rev Cancer       Date:  2010-01       Impact factor: 60.716

5.  Mad2 and BubR1 modulates tumourigenesis and paclitaxel response in MKN45 gastric cancer cells.

Authors:  J Bargiela-Iparraguirre; L Prado-Marchal; N Pajuelo-Lozano; B Jiménez; R Perona; I Sánchez-Pérez
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

6.  Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint.

Authors:  Tamotsu Sudo; Masayuki Nitta; Hideyuki Saya; Naoto T Ueno
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

7.  Dual roles of human BubR1, a mitotic checkpoint kinase, in the monitoring of chromosomal instability.

Authors:  Hyun Jin Shin; Kwan Hyuck Baek; Ae Hwa Jeon; Moon Taek Park; Su Jae Lee; Chang Mo Kang; Hyun Sook Lee; Seong Ho Yoo; Doo Hyun Chung; Young Chul Sung; Frank McKeon; Chang Woo Lee
Journal:  Cancer Cell       Date:  2003-12       Impact factor: 31.743
  7 in total
  1 in total

1.  Specific binding-induced modulation of the XCL1 metamorphic equilibrium.

Authors:  Acacia F Dishman; Francis C Peterson; Brian F Volkman
Journal:  Biopolymers       Date:  2020-09-28       Impact factor: 2.505
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.